Splenic iron decreases without change in volume or liver parameters during luspatercept therapy
- PMID: 37704579
- DOI: 10.1182/blood.2023021839
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy
Abstract
Splenic iron decreased whereas liver iron was stable during luspatercept therapy in some individuals with thalassemia. This suggests a reduction of ineffective erythropoiesis changes the organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron content. This article describes data from subjects enrolled in BELIEVE (NCT02604433) and BEYOND (NCT03342404).
© 2023 by The American Society of Hematology.
Comment in
-
Deironing the spleen with luspatercept.Blood. 2023 Nov 30;142(22):1856-1858. doi: 10.1182/blood.2023022548. Blood. 2023. PMID: 38032674 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical